Stockreport

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis [Yahoo! Finance]

Cabaletta Bio, Inc.  (CABA) 
PDF internal organ fibrosis, face limited treatment options as current therapies provide only modest effects and focus on treating the complications associated with the dise [Read more]